Register a trial

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06161025




Registration number
NCT06161025
Ethics application status
Date submitted
27/11/2023
Date registered
7/12/2023

Titles & IDs
Public title
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Scientific title
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Secondary ID [1] 0 0
REJOICE-Ovarian01
Secondary ID [2] 0 0
DS6000-109
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Womb (Uterine or endometrial cancer)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - R-DXd
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Topotecan
Treatment: Drugs - PLD

Experimental: Part A: R-DXd 4.8mg/kg Q3W - Participants will be randomized to receive intravenous R-DXd administered at a dose of 4.8 mg/kg every 3 weeks (Q3W).

Experimental: Part A: R-DXd 5.6 mg/kg Q3W - Participants will be randomized to receive intravenous R-DXd administered at a dose of 5.6 mg/kg every 3 weeks (Q3W).

Experimental: Part A: R-DXd 6.4 mg/kg Q3W - Participants will be randomized to receive intravenous R-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).

Experimental: Part B: R-DXd RP3D Q3W - Participants will be randomized to receive intravenous R-DXd administered at the Recommended Phase 3 Dose (RP3D) every 3 weeks (Q3W).

Active comparator: Part B: Investigator's Choice - Participants will be randomized to receive intravenous treatment with investigator's choice of paclitaxel, pegylated liposomal doxorubicin (PLD), gemcitabine, or topotecan.


Treatment: Drugs: R-DXd
R-DXd will be administered as an intravenously (IV) infusion

Treatment: Drugs: Gemcitabine
Gemcitabine will be administered as an IV infusion

Treatment: Drugs: Paclitaxel
Paclitaxel will be administered as an IV infusion

Treatment: Drugs: Topotecan
Topotecan will be administered as an IV infusion

Treatment: Drugs: PLD
PLD will be administered as an IV infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)
Timepoint [1] 0 0
From date of randomization to data cut off, up to 18 months
Primary outcome [2] 0 0
Progression-free Survival (PFS) Based on BICR Assessment (Part B)
Timepoint [2] 0 0
From date of randomization to data cut off, up to 26 months
Primary outcome [3] 0 0
Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part B)
Timepoint [3] 0 0
From date of randomization to data cut off, up to 16 months
Secondary outcome [1] 0 0
Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment
Timepoint [1] 0 0
From date of randomization to data cut off, up to 30 months
Secondary outcome [2] 0 0
Duration of Response (DOR)
Timepoint [2] 0 0
From date of randomization to data cut off, up to 40 months
Secondary outcome [3] 0 0
Progression-free Survival (PFS) Based on BICR and Investigator Assessment (Part A)
Timepoint [3] 0 0
From date of randomization to data cut off, up to 30 months
Secondary outcome [4] 0 0
Disease Control Rate (DCR)
Timepoint [4] 0 0
From date of randomization to data cut off, up to 40 months
Secondary outcome [5] 0 0
Overall Survival (OS)
Timepoint [5] 0 0
From date of randomization to data cut off, up to 40 months
Secondary outcome [6] 0 0
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Timepoint [6] 0 0
From first dose to data cut off, up to 40 months
Secondary outcome [7] 0 0
Pharmacokinetic (PK) Analysis: Maximum Plasma Drug Concentration (Cmax) of R-DXd
Timepoint [7] 0 0
From first dose to data cut off, up to 40 months
Secondary outcome [8] 0 0
Pharmacokinetic (PK) Analysis: Time to Reach Maximum Plasma Drug Concentration (Tmax) of R-DXP
Timepoint [8] 0 0
From first dose to data cut off, up to 40 months
Secondary outcome [9] 0 0
Pharmacokinetic (PK) Analysis: Area Under the Concentration-Time Curve (AUC) of R-DXd
Timepoint [9] 0 0
From first dose to data cut off, up to 40 months
Secondary outcome [10] 0 0
Pharmacokinetic (PK) Analysis: Terminal Half-Life (t1/2) of R-DXd
Timepoint [10] 0 0
From first dose to data cut off, up to 40 months
Secondary outcome [11] 0 0
Percentage of Participants With Treatment Emergent Antidrug Antibody (ADA)
Timepoint [11] 0 0
From baseline to data cut off, up to 40 months
Secondary outcome [12] 0 0
Percentage of Participants With Cancer Antigen 125 (CA-125) Response Rate
Timepoint [12] 0 0
From baseline to data cut off, up to 40 months
Secondary outcome [13] 0 0
Cadherin-6 (CDH6) protein expression in tumor tissue as determined by immunochemistry assay and correlation with ORR, DoR, PFS and OS
Timepoint [13] 0 0
From baseline to data cut off, up to 40 months
Secondary outcome [14] 0 0
Change in Score in the Quality of Life (QoL) Questionnaire
Timepoint [14] 0 0
From baseline to data cut off, up to 40 months
Secondary outcome [15] 0 0
Time to Next Treatment (TTNT)
Timepoint [15] 0 0
From date of randomization to data cut off, up to 40 months
Secondary outcome [16] 0 0
Progression-free Survival 2 (PFS2) Based on Investigator Assessment
Timepoint [16] 0 0
From date of randomization to data cut off, up to 40 months

Eligibility
Key inclusion criteria
* Sign and date the informed consent form prior to the start of any study-specific qualification procedures.
* Age =18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed.
* Participants with histologically or cytologically documented high-grade serous ovarian cancer (OVC), high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer.
* Participants must have at least 1 lesion, not previously irradiated, amenable to biopsy, and must consent to provide a pretreatment biopsy and on-treatment biopsy tissue sample (on-treatment biopsy sample not required for the Phase 3 part of the study). Fresh pretreatment biopsy may be waived for subjects who consent to provide an archival tumor tissue sample from a lesion not previously irradiated, performed within 6 months of consent, and performed after treatment with their most recent cancer therapy regimen.
* Has received at least 1 but no more than 3 prior systemic lines of anticancer therapy:

* Neoadjuvant +/-adjuvant considered 1 line of therapy.
* Maintenance therapy (eg, bevacizumab, poly-ADP ribose polymerase [PARP] inhibitors) will be considered part of the preceding line of therapy.
* Therapy changed due to toxicity in the absence of progression will be considered part of the same line.
* Hormonal therapy will be counted as a separate line of therapy, unless it was given as maintenance.
* At least 1 line of therapy containing bevacizumab, unless the subject is not eligible for treatment with bevacizumab due to precautions/intolerance. Note: Subjects must have progressed radiologically on or after their most recent line of systemic therapy. Biochemical progression will not be considered progression for this study.
* Has platinum-resistant disease. If a subject had only 1 line of platinum therapy, must have received at least 4 cycles of platinum, must have had a best response of not PD, and then progressed between >90 and =180 days after the date of the last dose of platinum If a subject had 2 or 3 lines of platinum therapy, must have received at least 2 cycles of platinum and have progressed on or within 180 days after the date of the last dose of platinum.
* Has had prior poly-ADP ribose polymerase (PARP) inhibitors for participants with documented breast cancer gene mutation (germline and/or somatic), unless the participant is not eligible for treatment with a PARP inhibitor.
* Has had prior treatment with mirvetuximab soravtansine for participants with documented high-folate receptor alpha expression, unless the participant is not eligible for treatment with mirvetuximab soravtansine due to precautions/intolerance, or if the treatment is not approved or available locally.
* Has at least 1 measurable lesion evaluated by computed tomography or magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per investigator assessment.
* Eastern Cooperative Oncology Group performance status of 0 or 1.
* Required baseline local laboratory data (within 7 days before start of study drug administration):

* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)

* 3.0 × upper limit of normal (ULN) in subjects with no liver metastasis and
* 5.0 × ULN in subjects with liver metastasis
* Total bilirubin (TBL) =1.5 × ULN (<3 × ULN for subjects with Gilbert's syndrome or liver metastasis at baseline)
* Absolute neutrophil count =1.5 × 109/L (growth factor support allowed up to 14 days before laboratory assessment for eligibility)
* Platelet count =100 × 109/L (transfusion allowed up to 14 days before laboratory assessment for eligibility)
* Hemoglobin =9.0 g/dL (transfusion and/or growth factor support allowed up to 14 days before laboratory assessment for eligibility)
* Creatinine clearance =30 mL/min as calculated using the Cockcroft-Gault equation
* Serum albumin =2.5 g/dL
* Adequate blood clotting function: International normalized ratio and either activated partial thromboplastin time or partial thromboplastin time =1.5 × ULN, unless the subject is receiving anticoagulant therapy as long as activated partial thromboplastin time or partial thromboplastin time is within the therapeutic range of intended use of anticoagulants
* If the participant is a female of childbearing potential, she must have a negative serum pregnancy test at 72 hours before the first dose of study drug and must be willing to use highly effective birth control upon enrollment, during the Treatment Period, and for 7 months following the last dose of study drug. A female is considered of childbearing potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months) unless permanently sterile (undergone a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) with surgery at least 1 month before the first dose or confirmed by follicle-stimulating hormone test.
* Female participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study drug administration.
* Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
* For Phase 3 (Part B) only: Participants must be eligible for one of the treatments included in the Investigator's choice of chemotherapy arm and must not have received it previously for OVC.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Has clear cell, mucinous, or sarcomatous histology, mixed tumors containing any histology, or low-grade/borderline OVC.
* Inadequate washout period before Cycle 1 Day 1, defined as follows:

* Major surgery <28 days
* Radiation therapy <28 days (if palliative stereotactic radiation therapy without abdominal radiation, =14 days)
* Systemic anticancer therapy (including antibody-drug therapy, retinoid therapy, and hormonal therapy) <28 days or 5 half-lives, whichever is shorter, before starting study drug
* Chloroquine/hydroxychloroquine <14 days
* Exposure to another investigational drug within 28 days prior to start of study treatment or current participation in other therapeutic investigational procedures
* Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. Subjects with untreated and asymptomatic brain metastases or subjects with treated brain metastases who are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy, at the investigator's discretion. Note: If there is a history or suspicion of central nervous system metastasis, a CT scan of the head or MRI of the brain must be performed at baseline.
* Any of the following within the past 6 months prior to randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event.
* Uncontrolled or significant cardiovascular disease, including the following:

* QT interval corrected with Fridericia's formula interval >470 ms (average of triplicate determinations).
* Diagnosed or suspected long QT syndrome or known family history of long QTsyndrome.
* History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.
* The participant has bradycardia of less than 50 bpm (as determined by central reading), unless the subject has a pacemaker.
* History of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.
* Myocardial infarction within 6 months prior to screening.
* Uncontrolled angina pectoris within 6 months prior to screening.
* New York Heart Association Class 3 or 4 congestive heart failure.
* Left ventricular ejection fraction <50% or institutional lower limit of normal as measured by echocardiography or multigated acquisition (MUGA) scan.
* Coronary/peripheral artery bypass graft within 6 months prior to screening
* Uncontrolled hypertension (resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg)
* Complete left or right bundle branch block.
* Has a history of (noninfectious) ILD/pneumonitis that required corticosteroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months of the study enrollment, severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, pleural effusion, etc) and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc), or prior pneumonectomy.
* Chronic steroid treatment (>10 mg/day), with the exception of the following:

* Inhaled steroids for asthma or COPD
* Mineralocorticoids (eg, fludrocortisone) for subjects with orthostatic hypotension
* Topical steroids for mild skin conditions
* Low-dose supplemental corticosteroids for adrenocortical insufficiency
* Premedication for treatment groups and/or premedication in case of any hypersensitivity
* Intra-articular steroid injections
* History of malignancy other than epithelial OVC, primary peritoneal cancer, or fallopian tube cancer within 3 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (eg, 5-year OS rate >90%) and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, nonmelanoma skin carcinoma, ductal carcinoma in situ, or Stage 1 uterine cancer).
* Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE Version 5.0, Grade =1 or baseline. Note: Subjects may be enrolled with chronic, stable Grade 2 toxicities (defined as no worsening to Grade >2 for 3 months prior to randomization and managed with SOC treatment) that the investigator deems related to previous anticancer therapy, following discussion with the Sponsor, such as the following:

* Chemotherapy-induced neuropathy
* Fatigue
* Endocrinopathies, which may include hypothyroidism, hyperthyroidism, Type 1 diabetes, hyperglycemia, and adrenal insufficiency
* Skin pigmentation (vitiligo)
* Prior exposure to other CDH6-targeted agents or an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan or datopotamab deruxtecan).
* History of hypersensitivity to any excipients in the R-DXd or any known contraindication to treatment with, including hypersensitivity to, the study drug(s).
* Has a known human immunodeficiency virus (HIV) infection that is not well controlled. Subjects must be tested for HIV viral load during the Screening Period if acceptable by local regulations or institutional review boards (IRBs)/ethics committees (ECs). All the following criteria are required to define an HIV infection that is well controlled: undetectable viral ribonucleic acid (RNA) load, CD4+ counts/levels of >350 cells/µL, no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months, and stable for at least 3 weeks on the same anti-HIV retroviral medications. If an HIV infection meets the above criteria, the subject's viral RNA load and CD4+ cell count should be monitored per local SOC (eg, Q3M).
* Has any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses or active infection, substance abuse) or other factors that, in the investigator's opinion, makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.
* Has an active or uncontrolled hepatitis B and/or hepatitis C infection. Subjects must be tested for hepatitis B (hepatitis B virus surface antigen [HBsAg] and anti-hepatitis B core antigen [HBc]) and hepatitis C virus antibody (HCV Ab) during the Screening Period. Subjects are eligible if they meet the following conditions:

1. Have been curatively treated for hepatitis C virus (HCV) infection as demonstrated by undetectable HCV RNA
2. Have received hepatitis B virus (HBV) vaccination with only anti-hepatitis B surface antibody (HBs) positivity and no clinical signs of hepatitis
3. Are HBsAg- and anti-HBc+ (ie, those who have cleared HBV after infection) and meet conditions i to iii of criterion "d" below
4. Are HBsAg+ with chronic HBV infection (lasting 6 months or longer) and meet conditions i to iii below: (i) HBV DNA viral load <2000 IU/mL (ii) Have normal transaminase values, or, if liver metastases are present, abnormal transaminases with a result of AST/ALT <3 × ULN that are not attributable to HBV infection (iii) Start or maintain antiviral treatment if clinically indicated as per the Investigator
* Female who is pregnant or breastfeeding or intends to become pregnant during the study.
* Psychological, social, familial, or geographical factors that would prevent regular follow-up.
* Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the subject; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
* Has a history of receiving live-attenuated vaccine (messenger RNA [mRNA] and replication-deficient adenoviral vaccines are not considered attenuated live vaccines) within 30 days prior to the first exposure to study intervention.
* For Phase 3 (Part B) only: Subjects are ineligible if they have a history of any contraindication included in the approved local label for the control group treatment.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/02/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2029
Actual
Sample size
Target
650
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
GenesisCare St Andrews Hospital - South Australia
Recruitment hospital [2] 0 0
GenesisCare North Shore (Oncology) - St Leonards
Recruitment postcode(s) [1] 0 0
- South Australia
Recruitment postcode(s) [2] 0 0
- St Leonards
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Florida
Country [2] 0 0
United States of America
State/province [2] 0 0
New York
Country [3] 0 0
United States of America
State/province [3] 0 0
Oklahoma
Country [4] 0 0
Canada
State/province [4] 0 0
Montreal
Country [5] 0 0
Canada
State/province [5] 0 0
Toronto
Country [6] 0 0
China
State/province [6] 0 0
Beijing
Country [7] 0 0
China
State/province [7] 0 0
Chongqing
Country [8] 0 0
China
State/province [8] 0 0
Fuzhou
Country [9] 0 0
China
State/province [9] 0 0
Guangzhou
Country [10] 0 0
China
State/province [10] 0 0
Hangzhou
Country [11] 0 0
China
State/province [11] 0 0
Jinan
Country [12] 0 0
China
State/province [12] 0 0
Nanning
Country [13] 0 0
China
State/province [13] 0 0
Shanghai
Country [14] 0 0
China
State/province [14] 0 0
Tainan
Country [15] 0 0
China
State/province [15] 0 0
Tianjin
Country [16] 0 0
China
State/province [16] 0 0
Wuhan
Country [17] 0 0
Czechia
State/province [17] 0 0
Hradec Kralove -Novy Hradec Kralove
Country [18] 0 0
Czechia
State/province [18] 0 0
Praha 2
Country [19] 0 0
Czechia
State/province [19] 0 0
Praha 5
Country [20] 0 0
Czechia
State/province [20] 0 0
Praha
Country [21] 0 0
France
State/province [21] 0 0
Caen Cedex 05
Country [22] 0 0
France
State/province [22] 0 0
Dijon cedex
Country [23] 0 0
France
State/province [23] 0 0
Lyon
Country [24] 0 0
France
State/province [24] 0 0
Marseille cedex
Country [25] 0 0
France
State/province [25] 0 0
Montpellier
Country [26] 0 0
France
State/province [26] 0 0
Nantes cedex 2
Country [27] 0 0
France
State/province [27] 0 0
Paris cedex 12
Country [28] 0 0
France
State/province [28] 0 0
Plérin
Country [29] 0 0
France
State/province [29] 0 0
Saint Cloud
Country [30] 0 0
France
State/province [30] 0 0
Vandoeuvre les Nancy
Country [31] 0 0
Germany
State/province [31] 0 0
Mannheim
Country [32] 0 0
Italy
State/province [32] 0 0
Aviano
Country [33] 0 0
Italy
State/province [33] 0 0
Catania
Country [34] 0 0
Italy
State/province [34] 0 0
Firenze
Country [35] 0 0
Italy
State/province [35] 0 0
Milano
Country [36] 0 0
Italy
State/province [36] 0 0
Napoli
Country [37] 0 0
Italy
State/province [37] 0 0
Roma
Country [38] 0 0
Italy
State/province [38] 0 0
Rozzano
Country [39] 0 0
Italy
State/province [39] 0 0
Torino
Country [40] 0 0
Japan
State/province [40] 0 0
Chuo-ku
Country [41] 0 0
Japan
State/province [41] 0 0
Fukuoka-shi
Country [42] 0 0
Japan
State/province [42] 0 0
Hidaka-shi
Country [43] 0 0
Japan
State/province [43] 0 0
Kashiwa-shi
Country [44] 0 0
Japan
State/province [44] 0 0
Koto-ku
Country [45] 0 0
Japan
State/province [45] 0 0
Minato-ku
Country [46] 0 0
Japan
State/province [46] 0 0
Nagoya-shi
Country [47] 0 0
Japan
State/province [47] 0 0
Niigata-shi
Country [48] 0 0
Japan
State/province [48] 0 0
Osaka-shi
Country [49] 0 0
Japan
State/province [49] 0 0
Sapporo-shi
Country [50] 0 0
Japan
State/province [50] 0 0
Shiwa-gun
Country [51] 0 0
Japan
State/province [51] 0 0
Sunto-gun
Country [52] 0 0
Korea, Republic of
State/province [52] 0 0
Seongnam-si
Country [53] 0 0
Korea, Republic of
State/province [53] 0 0
Seoul
Country [54] 0 0
Poland
State/province [54] 0 0
Gdansk
Country [55] 0 0
Poland
State/province [55] 0 0
Siedlce
Country [56] 0 0
Portugal
State/province [56] 0 0
Amadora
Country [57] 0 0
Spain
State/province [57] 0 0
Barcelona
Country [58] 0 0
Spain
State/province [58] 0 0
Jaén
Country [59] 0 0
Spain
State/province [59] 0 0
Madrid
Country [60] 0 0
Spain
State/province [60] 0 0
Pamplona
Country [61] 0 0
Spain
State/province [61] 0 0
Valencia
Country [62] 0 0
Taiwan
State/province [62] 0 0
Taichung
Country [63] 0 0
Taiwan
State/province [63] 0 0
Taipei
Country [64] 0 0
Taiwan
State/province [64] 0 0
Taoyuan City
Country [65] 0 0
United Kingdom
State/province [65] 0 0
Bath

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Daiichi Sankyo
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Global Clinical Leader
Address 0 0
Daiichi Sankyo
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Medical Director Contact for Clinical Trial Information
Address 0 0
Country 0 0
Phone 0 0
908-992-6400
Fax 0 0
Email 0 0
CTRinfo@dsi.com
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF)
When will data be available (start and end dates)?
Available to whom?
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: https://vivli.org/ourmember/daiichi-sankyo/


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT06161025